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Abstract
The serralysin family of metalloproteases is associated with the virulence of multiple gram-negative human pathogens,
including Pseudomonas aeruginosa and Serratia marcescens. The serralysin proteases share highly conserved catalytic
domains and show evolutionary similarity to the mammalian matrix metalloproteases. Our previous studies demonstrated
that alkaline protease (AP) from Pseudomonas aeruginosa is capable of activating the epithelial sodium channel (ENaC),
leading to an increase in sodium absorption in airway epithelia. The serralysin proteases are often co-expressed with
endogenous, intracellular or periplasmic inhibitors, which putatively protect the bacterium from unwanted or unregulated
protease activities. To evaluate the potential use of these small protein inhibitors in regulating the serralysin induced
activation of ENaC, proteases from Pseudomonas aeruginosa and Serratia marcescens were purified for characterization
along with a high affinity inhibitor from Pseudomonas. Both proteases showed activity against in vitro substrates and could
be blocked by near stoichiometric concentrations of the inhibitor. In addition, both proteases were capable of activating
ENaC when added to the apical surfaces of multiple epithelial cells with similar slow activation kinetics. The high-affinity
periplasmic inhibitor from Pseudomonas effectively blocked this activation. These data suggest that multiple
metalloproteases are capable of activating ENaC. Further, the endogenous, periplasmic bacterial inhibitors may be useful
for modulating the downstream effects of the serralysin virulence factors under physiological conditions.
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Introduction
Opportunistic pathogens secrete multiple virulence factors to
modulate interactions with the host, to acquire nutrients from the
environment and to facilitate adhesion and colonization to a
variety of substrates [1–4]. Pseudomonas aeruginosa secretes a series of
proteases that target host proteins to modulate the immune
response and to facilitate colonization in infected tissues. Bacterial
adherence and colonization may be facilitated by the degradation
of host immune and signaling proteins that would otherwise
initiate or potentiate the host response. Alternatively, remodeling
the local environment of a bacterium may promote its adherence
or growth.
Alkaline protease (AP) has been shown to play a role in multiple
modes of Pseudomonas infection [2,4–8]. The AP is a member of the
serralysin family of proteases, belonging to the larger M10 family
of Zn2+ metalloproteases [9,10]. Structurally, AP is composed of
two globular domains: an N-terminal catalytic domain and a C-
terminal Ca2+-binding domain. The N-terminal catalytic domain
contains the canonical HEXXHXXGXXH motif associated with
Zn2+ coordination in the metalloproteases. This domain shows
significant structural similarity to a variety of metalloproteases,
including the human matrix metalloproteases. The C-terminal
domain of AP contains multiple Ca2+-binding motifs associated
with the Repeats-in-ToXin (RTX) family of bacterial virulence
factors [11–13]. This domain has previously been shown to bind
Ca2+, which induces its folding and the folding and activation of
the N-terminal protease domains [14–16]. Calcium is tightly
coordinated by conserved asparatate- and glycine-rich nonapep-
tide RTX repeats, as seen in the high-resolution structures of
Pseudomonas AP and serralysin (SmP) from Serratia marcescens [9,10].
This mode of Ca2+-mediated regulation is likely a key feature of
the serralysin proteases, as well as the family of RTX virulence
factors and toxins [11,12,17].
Bacterial species producing serralysins often co-express inhib-
itors that putatively block the function of their respective proteases
in the cytosol or periplasm [18,19]. In Pseudomonas aeruginosa, the
apr operon is genomically encoded proximal to a high-affinity
inhibitor, aprI, of the protease gene, aprA [20]. This inhibitor (AP
Inh) is localized to the periplasm of the bacterial cells and
putatively protects the cells from the AP enzymatic activity. It is
unclear how this occurs as the protease is not normally localized to
the periplasm [21]. Structural studies have shown that this
inhibitor binds in the active site of AP and is coordinated by the
Zn2+ ion and other protein-protein contacts with the surfaces of
the N-terminal catalytic domain [19,21]. Further, these studies
suggest that the inhibitor binds with high affinity (4 pM) to the AP
active site [19].
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The active AP has previously been correlated with the virulence
of Pseudomonas in cystic fibrosis (CF) [4,7,8,22,23]. Similarly,
expression of the serralysins from Serratia marcescens has been shown
to exacerbate corneal injury [24,25]. While the pathophysiological
mechanisms in patients have not been fully elucidated, AP has
been shown to cleave bacterial flagellin, host signaling molecules
and the epithelial sodium channel (ENaC) [26–28]. Cleavage of
flagellin and cytokines would putatively alter the host response to
the pathogen, while ENaC cleavage would be predicted to
remodel the airway surface hydration state, reduce muco-cilliary
clearance, and facilitate bacterial adherence and colonization. The
combined effects of blunting the host immune response and
altering ion channel activity would putatively contribute to an
increase in bacterial load within the airway and the apparent
virulence of the pathogen.
To evaluate the potential use of the aprI inhibitor as a modulator
of AP activity in airway epithelial cells, AP and AP Inh were
purified. Tight association and protease inhibition were measured
in vitro and demonstrated that near stoichiometric addition of the
inhibitor completely bound the protease and inhibited its activity.
This inhibition was blocked with N-terminal fusions to the
inhibitor, consistent with the known structures of the protease-
inhibitor complexes [18,19]. ENaC-mediated sodium transport in
a model cell line and primary airway cultures confirmed that AP
addition to the apical bathing surface activated ENaC and that
near stoichiometric addition of AP Inh blocked the observed
ENaC activation. Similarly, ENaC activation was observed in
response to apical addition of serralysin from S. marcescens. This
activation was blocked by the addition of the purified AP Inh
protein. These data show that multiple M10/serralysin family
members can activate ENaC and more broadly implicate the M10
protease family as modulators of ENaC activity. Further, the
native Pseudomonas inhibitor is effective as an inhibitor for multiple
M10 proteases under physiological conditions. These results
suggest that serralysin-mediated ENaC activation requires active
protease and that modulation of these protease activities could
potentially be leveraged to effectively reduce the virulence
associated with bacterial metalloprotease production and secre-
tion.
Materials and Methods
Protein expression and purification
Alkaline protease from Pseudomonas aeruginosa was purified under
denaturing conditions and refolded as previously described using a
T7 regulated pET vector for expression [16]. Serralysin from
Serratia marcescens (SmP) was similarly expressed and purified under
denaturing conditions using a pBAD expression vector with
arabinose induction. Briefly, donor cultures were grown overnight
at 37uC under antibiotic selection. The donor cultures were used
to inoculate 1 liter expression cultures that were grown to mid-log
phase (OD600,0.6–0.8) before induction. Induction was accom-
plished with the addition of 1 mM IPTG or 0.02% w/v arabinose.
Proteins were expressed at 37uC for 4–6 hours and cultures were
harvested by centrifugation. Cells were resuspended (50 mM Tris,
150 mM NaCl, pH 7.2) lysed by sonication and inclusion bodies
were collected by centrifugation (14, 000 G RCF, 30 minutes,
4uC). The insoluble material was resuspended (50 mM Tris,
150 mM NaCl, 6 M GuHCl, pH 7.2) and loaded on a Ni-NTA
column (GE Life Sciences) equilibrated in the resuspension buffer.
The column was washed with resuspension buffer supplemented
with 60 mM imidazole and the protein was eluted with 400 mM
imidazole in resuspension buffer. The denatured protein was
further purified using a sephacryl S200 Hi-Prep gel filtration
column (GE Life Sciences) (50 mM Tris, 150 mM NaCl, 6 M
GuHCl, pH 7.2) and stored at 4uC before refolding and use.
The aprI inhibitor (Inh) was PCR amplified from PAO1
genomic DNA (ATCC) and cloned into a pET vector as a C-
terminal fusion to a 6xHis Smt3 tag [29]. The protein was
expressed as described above for AP and was purified from the
supernatant after lysis (50 mM Tris, 150 mM NaCl, pH 7.2) and
centrifugation at 40,000 G RCF for 30 minutes at 4uC. The
protein was loaded onto a Ni-NTA column equilibrated in lysis
buffer. The column was washed in buffer supplemented with
60 mM imidazole and eluted in buffer supplemented with
400 mM imidazole. The Smt3 fusion was cleaved using Ulp1
protease at 4uC and the resulting products were separated using a
sephacryl S200 Hi-Prep column and a second Ni-NTA column.
The N-terminal Smt3 and Ulp1 protease were immobilized on the
second Ni-NTA column while the AP Inh inhibitor passed
through the column without binding. The Smt3 N-terminal tag
was left intact as a fusion to AP Inh for experiments evaluating the
specificity of the inhibitor binding to AP (Inh*).
Protease refolding, activity and inhibition assays
The AP and SmP proteases were refolded as previously
described [16,26]. Briefly, proteases in GuHCl were rapidly
diluted into refolding buffer (50 mM Tris, 150 mM NaCl, 2 mM
CaCl2) on ice for 15 minutes. The refolding reactions were
clarified by centrifugation (21,000 G RCF, 15 minutes, 4uC) or by
filtration (100 kDa MWCO, Ultracell concentrators, Millipore)
prior to use. Protease activity was assessed using fluorescently
labeled protease substrates. A highly conjugated casein protein
(EnzCheck, Invitrogen) and a metalloprotease specific peptide
substrate (Mca-K-P-L-G-L-Dpa-A-R-NH2; Mca: (7-methoxycou-
marin-4-yl)acetyl, Dpa: N-3-(2, 4-Dinitrophenyl)-L-2,3-diamino-
propionyl; R&D Systems) were chosen based on previous studies
of AP. Protease activities were assessed, in the presence and
absence of AP Inh, in 96 well plate format using a BioTek Synergy
4 multi-mode plate reader in endpoint or kinetic mode and
velocity parameters were fit using Gen5 software (BioTek).
Analytical gel filtration experiments were performed using a
TOSOH QC-PAK GFC 200 column on a Shimadzu Prominence
HPLC. The column was pre-equilibrated using the refolding
buffer in the presence or absence of Ca2+ before the protein
injection. Protein elution was monitored by UV absorbance at 220
and 280 nm.
Cell culture and electrophysiology
Fisher rat thyroid (FRT) cells (ATCC) were maintained in
DMEM/F12 media supplemented with 5% FBS, 10 mU/ml
TSH, 0.01 mg/ml insulin, 10 nM hydrocortisone, 0.005 mg/ml
transferrin, 10 ng/ml somatostatin, 10 ng/ml glycyl-L-histidyl-L-
lysine acetate. FRT Cultured mouse cortical collecting duct
(mCCD) kidney epithelial cells were kindly provided by Bernard
Rossier and Laurent Schild, Universite´ de Lausanne, Switzerland,
and maintained as previously described [30]. Dr. Joseph Pilewski
of the University of Pittsburgh Cystic Fibrosis Research Center
Cell Core provided primary human bronchial epithelial (HBE)
cells, under a protocol approved by The University of Pittsburgh
Investigational Review Board [26,31]. Primary cells were routinely
maintained as previously described. For short-circuit current (ISC)
recordings, cells were grown on Transwell inserts until a confluent,
high–resistance monolayer was obtained. These inserts were
mounted in modified Ussing chambers (P2300, Physiological
Instruments) in a modified Ringer’s solution and continuously
short-circuited with an automatic voltage clamp (VCC MC8,
Physiological Instruments) as previously described [32–34].
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Transepithelial resistance was monitored throughout the recording
by periodically applying a 2 mV pulse via an automated pulse
generator. Recordings were digitized and analyzed using Power-
Lab (AD Instruments, Colorado Springs, CO).
To isolate the action of the serralysin proteases from serine
proteases, which are known to activate ENaC, cells were
preincubated with 10 mM camostat mesylate (Santa Cruz
Biotechnology) for 60 minutes prior to recordings. Camostat was
maintained in the apical hemi-chamber (10 mM) during serralysin
activation and did not inhibit the activity of the AP and SmP
proteases when compared to cells without camostat addition (not
shown) [35]. Prior to trypsin addition, the apical chamber was
washed with a five-fold volume exchange of warmed Ringer’s
solution to remove the camostat. The surface ENaC that was
uncleaved was subsequently activated by exogenous trypsin
addition (1 mM) as we have demonstrated [26]. No trypsin
activation was observed in recordings where the camostat was not
removed from the apical chamber, confirming the inhibition of a
serine protease under the experimental conditions.
A typical ISC recording included a 10-minute equilibration
period, followed by stimulation with trypsin, AP or serralysin, with
and without AP Inh. INa was determined by the addition of 10 mM
amiloride to the apical cell chamber at the end of each recording.
Maximal ENaC activity was generated by trypsin addition and
recorded ISC was normalized to the maximum trypsin-activated
INa. Protease concentrations were chosen to match the apparent
specific activities using the fluorescent assays described above and
as previously described.
Cell surface cleavage, biotinylation and western blotting
Cleavage of c-ENaC at the apical surface was accomplished
using a modified double-immunoprecipitation protocol. FRT cells
were grown on 75 cm2 flasks (Thermo Fisher) to obtain sufficient
cells to seed ,36106 cells per filter. Cells were harvested and
transfected in suspension using Lipofectamine 2000 (Life Tech-
nologies) following manufacturer’s protocols. Cells were incubated
with the lipid/DNA complex for 5 hours before seeding directly
onto 6-well filter supports at superconfluency. A total of 4 transwell
filters (Corning 6-well, 2.4 cm diameter) were used for each
condition and pooled following biotinylation to obtain a single
sample. For the required 4 filters (1.26107 cells) equal concentra-
tions of untagged a- and b-ENaC and tagged c-ENaC were used
at a total DNA quantity of 10 mg [36]. Medium was replaced after
6 hours to fully supplemented medium (including FBS) as
described previously [33]. The FRT cells were allowed to form
a polarized monolayer, as confirmed by transepithelial resistance,
before surface biotinylation labeling [31].
To cleave surface ENaC, cells were treated with alkaline
protease as described for electrophysiological experiments. As a
control, trypsin was added to the apical surface. FRT cells were
incubated with protease and/or inhibitor for 30 minutes. Inserts
were then washed five times with ice-cold PBS containing Mg2+
and Ca2+ (PBS+CM). The cells were biotinylated at 4uC in borate
buffer (85 mM NaCl, 4 mM KCl, 15 mM Na2B4O7, 375 mg
biotin, pH 9) on the apical surface with the basolateral side of the
monolayer bathed in medium containing 10% FBS to prevent
basolateral biotinylation. After 20 min, cells were aspirated and
PBS+CM containing 10% FBS was placed on the cells to quench
the biotinylation. Monolayers were washed five times with ice-cold
PBS+CM with agitation, and the cells were lysed in 400 ml
biotinylation lysis buffer (0.4% sodium deoxycholate, 1% NP-40,
10 mM Tris-base, 50 mM EGTA, protease inhibitor cocktail II
(Roche)) per filter. Post-nuclear supernatant was obtained for
immunoprecipitation (IP) of ENaC using an anti-V5 antibody
(Novus Biologicals) conjugated to 100 ml protein-G beads. Samples
were incubated with rotation at 4uC overnight. Following IP beads
were washed three times in PBS containing 1% triton-X and
0.01% SDS. The isolated ENaC IP samples were next eluted from
the beads by incubating in 120 ml biotinylation lysis buffer
containing 30 ml 10% SDS for 10 min at room temperature.
The eluate was incubated with 75 ml pre-washed streptavidin
magnetic beads (Pierce/Thermo Scientific) at 4uC overnight with
rotation to enrich for the cell surface, biotinylated ENaC. Samples
were washed three times in biotinylation lysis buffer during
magnetic bead separation. After the final wash, beads were
resuspened in buffer with 30 ml of a 2 X sample buffer including
100 mM DTT heated to 95uC for 8 min and separated on a 8–
16% Tris-HEPES-SDS-PAGE precast gel (Bio-Rad). Samples
were transferred to nitrocellulose membranes (Millipore) using a
Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad) following the
manufacturer’s protocols and assessed by western blotting.
Western blots were quantified after digital capture (scanning)
using Adobe Photoshop CS.
Statistics and curve fitting
All data were analyzed using SigmaPlot (Systat, Chicago, IL).
Differences in in vitro protease activities were assessed using
Welch’s analysis of variance or student’s t-test. Differences in
summarized electrophysiological data were evaluated by t-tests
with p,0.05 considered statistically significant. Activation curves
were fit using SigmaPlot, and rate constants derived from the
plotted exponential rise curves (R-squared values ranged from 0.85
to 0.99).
Results
ENaC cleavage by active alkaline protease
The functional ENaC channel exists in the plasma membrane
as a putative trimer, normally composed of a-, b- and c-subunits
(Figure 1A). Trafficking and recycling of ENaC at the plasma
membrane regulate channel function. In addition, proteolytic
cleavage of sequences within the a- and c-subunits has been shown
to functionally activate the channel in the plasma membrane. Our
previous studies of ENaC activation demonstrate that the
Pseudomonas aeruginosa Zn2+ metalloprotease, alkaline protease, is
capable of activating ENaC in multiple primary and model
epithelial cells [26]. This activation required the presence of the c-
subunit and its protease-sensitive inhibitory peptide, as mutant c-
ENaC constructs lacking this regulatory sequence failed to show a
response to treatment with purified AP. The a-ENaC protease
sites did not appear to be functionally sensitive to the addition of
AP in Ussing chamber experiments.
To assess the cleavage state of c-ENaC in response to treatment
with the active AP, ENaC was expressed in confluent monolayers
of FRT cells. FRT cells were chosen as they robustly express
ENaC and can be transfected to provide sufficient channel protein
for cell surface analysis. Following transfection, polarization and
expression, purified AP was added to the apical cell surface and
allowed to cleave plasma membrane-resident protein. The cells
were then biotinylated and ENaC was immunoprecipitated. Cell
surface ENaC was captured by streptavidin pull-down and the
eluate was subsequently assessed by western blotting.
Under basal conditions, ENaC expressed robustly in FRT cells
(Figure 1B, Whole Cell). Isolation of the cell surface ENaC protein
allowed for the identification of ENaC proteolysis following
treatment with either AP or AP+AP Inh. Control cells, which
were left untreated with protease or treated solely with protease
inhibitors, showed two distinct ENaC bands. A high molecular
Serralysin Modulation of ENaC Channel Activity
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weight band, corresponding to full-length c-ENaC, was identified
at ,90 kDa (Figure 1B, Cell Surface, **). A second and less intense
band was observed at ,55 kDa and corresponded to a small
population of ENaC that was cleaved at the cell surface under
control conditions (Figure 1B, Cell Surface, *). This band likely arose
from cleavage events in the biosynthetic pathway or plasma
membrane that were not fully inhibited with the camostat
pretreatment.
The purified AP and AP Inh proteins were then assessed for
their ability to regulate c-ENaC cleavage biochemically. The
addition of AP to the apical surface of the FRT cells resulted in a
dramatic increase in the amount of cleaved c-ENaC observed by
western blotting. This increased cleavage resulted in a strong
enhancement of the ,55 kDa band seen by western blotting.
Densitometric analyses of the cleaved bands showed 54%610% of
the cell surface ENaC to be cleaved under these conditions. This
was consistent with the previously reported proteolytic activation
of c-ENaC. To assess the potential use of the Pseudomonas AP
inhibitor, both the AP and AP Inh were co-incubated on the FRT
cells. The inclusion of the AP Inh protein at 2:1 stoichiometry to
the concentration of AP resulted in a decrease in observed ENaC
cleavage, as seen by western blotting. Densitometric analyses of
the cleaved ENaC demonstrated that 23%66% of the cell surface
ENaC protein was cleaved (p,0.05 compared to AP treatment).
These data demonstrated that the AP Inh protein effectively
inhibited AP activity outside of the bacterial cell and could be used
to block ENaC cleavage.
Calcium-regulated folding and activation of the serralysin
proteases
To evaluate the potential that other bacterial metalloproteases
in the serralysin family could activate ENaC and be regulated by
the Pseudomonas protease inhibitor, proteases from Pseudomonas
aeruginosa and Serratia marcescens were purified for in vitro character-
ization and electrophysiological studies. Previous studies of the
folding of AP demonstrated that Ca2+-binding within the C-
terminal RTX repeats regulated protease folding with an apparent
affinity of 50–60 mM [16]. To evaluate the Ca2+ induced folding of
the serralysin proteases, AP and SmP were purified and refolded in
vitro. Previous studies have shown that this procedure is efficient,
with .85% of the protein being refolded in the presence of
saturating Ca2+ [16]. The function of both refolded proteases was
assessed using fluorescence-based assays to confirm activity. Two
assays using different substrates were chosen utilizing either
fluorophore-conjugated casein or a fluorophore-conjugated pep-
tide. In the presence of Ca2+, both AP and SmP showed significant
protease activities when compared with samples refolded without
Ca2+ (p,0.001) (Figure 2A). At equimolar concentrations, SmP
showed a modest increase in activity relative to AP using the casein
substrate. The SmP apparent activity was 123%+/214% when
compared to the activity of the refolded AP. In the absence of
Ca2+, both proteases showed minimal activity against the casein
substrate, consistent with the previously described Ca2+-regulated
folding and activation of the RTX proteases.
Similarly, both proteases showed a Ca2+-dependent activity
using a peptide substrate (Figure 2B). The peptide substrate was
chosen based on the structural similarity between AP, SmP and
mammalian matrix metalloproteases (MMP2 and MMP9) and
putatively provides a substrate with fewer structural constraints.
Millimolar concentrations of Ca2+ resulted in the activation of
both AP and SmP as detected by kinetic and endpoint assays. As
with the casein substrate, the SmP activity was consistently higher
than that of AP with the fluorogenic peptide. Using the peptide
substrate, the SmP produced 138%+/224% that activity of the
refolded AP. In the absence of Ca2+, only trace amounts of
protease activity could be detected (p,0.001). The casein and
peptide proteolysis data demonstrate that both the AP and SmP
are regulated by Ca2+ binding and can be similarly refolded in vitro.
To evaluate the stability of the refolded proteases, the proteins
were incubated for extended periods at 37uC and proteolytic
activity was subsequently evaluated. Similar auto-proteolysis/
protease competition experiments have been previously utilized to
probe the stabilities of other bacterial exoproteins [37]. Proteolytic
cleavage of the enzyme leads to a decrease in activity, which is
related to the accessibility of cleavage sites and the stability of the
native state. Once folded, both the AP and SmP proteases showed
Figure 1. ENaC cleavage by active AP. Cell surface cleavage of c-ENaC was assessed biochemically using purified AP and AP Inh. A, a cartoon
schematic of the ENaC channel is shown with the a-, b-, and c-subunits labeled. The protease sensitive tract in c-ENaC is shown as a gray box and
spans residues 139 to 181 [49]. B, cell surface cleavage of ENaC was assessed by western blotting. Total ENaC is shown for control cells (CNTL), AP
treated cells, or cell co-treated with AP and AP Inh from whole cell lysates, Whole Cell. The cell surface ENaC was assessed after biotinylation and
streptavidin capture, Cell Surface. From the cell surface pool of ENaC the full length (**) and cleaved (*) forms of the channel are observed. Actin was
used as a loading control and was not observed in biotinylated samples.
doi:10.1371/journal.pone.0100313.g001
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sustained activities after incubation at physiological temperatures
(Figure 2C). Following 24 hours incubation at 37uC, AP retained
63%+/28% activity. Similarly, SmP retained 54%+/214%
activity after a 24-hour incubation. The long-lived activity
demonstrated that secretion of these enzymes would provide for
sustained catalytic activity outside of the cell.
Binding and inhibition of AP by its inhibitor from
Pseudomonas
The RTX proteases are often co-expressed with endogenous
inhibitors that putatively protect the bacterial cell from unwanted
protease activity [18,19]. Previous studies have shown that the
inhibitor from Pseudomonas aeruginosa binds with high affinity to AP.
To evaluate the potential use of the inhibitor outside of the
bacterial cell, the inhibitor was purified for in vitro binding studies
and physiological experiments on epithelial cells.
Two forms of the inhibitor were produced with differing N-
termini. In Pseudomonas, the inhibitor is secreted into the periplasm
using an N-terminal signal sequence. The N-terminal residue,
generated after cleavage of the signal sequence in the periplasm, is
coordinated in the protease active site by the Zn2+ cofactor [19].
The inhibitor was expressed as a Smt3-fusion in E. coli with the
purification tag fused to the N-terminus in lieu of the signal
sequence. This fusion (AP Inh*) would putatively block binding of
the inhibitor to the active site of the protease and served as a
control for the inhibitor studies. Removal of the Smt3 provided the
N-terminus required for binding to the AP active site and provided
an active form of the inhibitor (AP Inh).
Binding of the inhibitor to AP and SmP was assessed using
analytical gel filtration and activity assays. The refolded proteases
ran as single symmetric peaks, as monitored by UV absorbance of
the column eluate (Figure 3A, C). Similarly, the inhibitor eluted as
a single, symmetrical peak when injected alone onto the column.
When the inhibitor was mixed in equimolar ratios with the
protease, the individual inhibitor and protease peaks decreased to
baseline and a new species appeared at a lower retention time.
Binding appeared to be tight as the peak shift appeared to be
complete and the shift resulted in a near symmetrical single peak
that represented protease bound to the inhibitor.
To assess the activities of AP and SmP in the presence of the
inhibitor, the fluorescence-based peptide activity assay was utilized
(Figure 3B, D). Activation of both AP and SmP was dependent on
Ca2+, as shown in Figure 1. The inclusion of Inh* showed minimal
effect on the activity of the AP or SmP. Small decreases in
apparent protease activity may be associated with a non-
fluorescent protein being included in the reaction and a dilution
of the reporter substrate. In contrast, inclusion of the inhibitor at
equimolar concentrations significantly reduced protease activity by
greater than 90% for both AP and SmP (p,0.001). This was
consistent with the binding seen in the analytical gel filtration. The
inhibitor alone, either Inh or Inh*, showed no protease activity.
Extended incubation (12–16 hours at 37uC) of both proteases with
Figure 2. Folding and activation of serralysins from Pseudmonas aeruginosa and Serratia marcescens. Protease activities were assessed for
both AP and SmP using a fluorescently-conjugated casein substrate, A, or a fluorescent metalloprotease peptide substrate, B. Addition of 2 mM Ca2+
to the refolding buffers resulted in robust folding and activation of both AP and SmP, as measured by protease activity. C, protease activity was
assessed immediately after refolding or following a 24 hour incubation at 37uC using the metalloprotease peptide substrate. Buffer controls are
subtracted from all samples and the activities are normalized to AP, A, B, or protease activity measured immediately after refolding, C. Data shown are
mean 6 standard deviation from n= 6 experiments. P,0.001, *.
doi:10.1371/journal.pone.0100313.g002
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the inhibitor did not lead to an increase in protease activity,
suggesting that inhibitor binding was tight and that the co-
incubation did not result in a decrease in the effectiveness of the
inhibitor over the time courses evaluated (data not shown).
Functional Regulation of ENaC by AP, SmP and the
serralysin inhibitor in mCCD cells
Previous studies of AP indicated that the protease, when
expressed by Pseudomonas or purified from recombinant sources,
was capable of activating ENaC [26]. To assess the effects of both
SmP and inhibitor, mCCD cells were chosen for electrophysio-
logical studies. These cells were chosen as they express ENaC at
high levels, form tight monolayers, and act as a robust model for
physiological measurement of ENaC activity [30]. Further, we
have previously shown that AP robustly activates ENaC in this cell
line. Cells were pretreated with camostat mesilate, an inhibitor of
serine proteases, to isolate the activities of AP and SmP on the cell
surface [35]. This inhibition results in an accumulation of ENaC
channels at the cell surface that can be evaluated by addition of
exogenous proteases [38]. The proteases, either alone or in
combination with the AP inhibitor were added to the apical baths
of Ussing chambers. As shown previously, AP was capable of
activating ENaC when ISC was measured in Ussing chambers.
Trypsin (1 mM) was used as a control to provide maximal ENaC
activation (complete cleavage) for each experiment. Amiloride
addition to the apical bath inhibited the protease-sensitive
currents, consistent with the measured current being mediated
by ENaC.
Addition of 300 nM AP resulted in an increase in ENaC activity
in the mCCD cells (Figure 4A, C). The kinetics of ENaC activation
were slower with AP than with trypsin, as previously reported [26].
This slow activation was sustained and little run down was seen
despite prolonged incubation times with AP. To further explore
the use of the endogenous AP inhibitor from Pseudomonas, the
inhibitor was added to the apical bath of Ussing chambers, prior to
the addition of protease. The inhibitor alone had no observable
impact on baseline ENaC activity (Figure 4B, C). As established in
vitro, the inhibitor binds tightly to AP and effectively abolishes its
activity at near equimolar concentrations (Figure 3). Pretreatment
of the apical surface with the 2:1 ratio of inhibitor: protease
blocked the activation of ENaC previously described for AP
(Figure 3B, C) in mCCD cells. Treatment with AP Inh effectively
blocked the AP-induced ENaC activation seen in the short circuit
measurements (p,0.005) (Figure 4C).
To assess the ability of SmP to activate ENaC, the SmP protein
was used for short-circuit current recordings. As previously
described for AP, addition of SmP to the apical bath of mCCD
cells resulted in an increase in ENaC current (Figure 4D). The
activation of ENaC was slower and more sustained than that
reported for trypsin. The addition of SmP resulted in an increase
of ,35% ENaC activation in mCCD cells, similar to that seen
with AP (Figure 4D, F). The AP Inh protein was then used to
assess its potential for modulation of the SmP-associated ENaC
Figure 3. Binding and inhibition of AP Inh to AP and SmP. Inhibition of protease activity was evaluated using purified AP and the
Pseudomonas aeruginosa AprI inhibitor. A, analytical gel filtration was used to assess complex formation between the refolded AP and the purified
inhibitor. Representative chromatograms are shown for protease, black line, the inhibitor, dark gray line, and the complex, light gray line. B, activity
assays were performed using the fluorescent peptide substrate for AP. C, analytical gel filtration was used to assess complex formation between the
refolded SmP and the purified inhibitor. Representative chromatograms are shown for the protease, black line, the inhibitor, dark gray line, and the
complex, light gray line. D, activity assays were performed using the fluorescent peptide substrate for AP. Data shown are mean6 standard deviation
for n= 5 experiments. P,0.001, *; n.s., not significant.
doi:10.1371/journal.pone.0100313.g003
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activation. Pre-incubation with the AP Inh protein resulted in a
complete loss of SmP-associated ENaC activation (p,0.005)
(Figure 4E, F). This inhibition was seen when the apical chamber
was pre-treated with a 2:1 ratio of inhibitor to protease or when
both proteins were added simultaneously. No differences in the
inhibition were seen with either treatment regime (data not
shown).
Activation of ENaC by both the AP and SmP was kinetically
slower than that seen by trypsin under maximal conditions. At
maximal dosage, AP activation of ENaC occurred with a time
constant ,5 fold slower than that measured for trypsin (p,0.05)
(Figure 4G). Similarly, SmP activation of ENaC occurred with a
time constant,3.5 fold slower than that of trypsin when evaluated
under maximally stimulating conditions (p,0.05). The measured
time constants for maximal activation were measured to be 28
seconds for trypsin, 144 seconds for AP and 98 seconds for SmP.
Functional Regulation of ENaC by AP, SmP and the
serralysin inhibitor in HBE cells
To assess the application of the AP inhibitor in the context of
primary airway cells, ENaC activation in human bronchial
epithelia (HBE) cell monolayers was assessed. Addition of AP to
the apical bath of HBE monolayers resulted in a robust and
sustained activation of ENaC (Figure 5A, C). The relative change
Figure 4. ENaC regulation in mCCD cells by the proteases and the AP inhibitor. The activation of ENaC was assessed using mCCD cells by
recording short circuit currents in Ussing chambers. A, a representative trace showing the activation of ENaC in mCCD cells is shown. B, a
representative trace of AP treatment after AP Inh pretreatment is shown. C, quantification of the relative currents seen after treatment with either AP
or AP and AP Inh for mCCD cells are shown. Basal currents are normalized to 100%. D, a representative trace showing the activation of ENaC by SmP
in mCCD cells is shown. E, a representative trace of SmP after AP Inh pretreatment is shown. F, quantification of the relative currents seen after
treatment with either SmP or SmP and AP Inh for mCCD cells is shown. G, the kinetics of ENaC activation are shown under conditions of maximal
stimulation using trypsin, closed circles, AP, closed triangles, or SmP, open circles. Time constants of ENaC activation are shown for each protease. Serial
addition of proteases and inhibitors is shown by the bars above the current trace and labelled. The period in the recording where the apical chamber
was washed to remove the serine protease inhibitor, camostat, is indicated with a W. Data shown are representative of at least five experiments.
P,0.004, *.
doi:10.1371/journal.pone.0100313.g004
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in HBE ENaC currents was larger than those seen in the mCCD
cells, with AP inducing a ,85% increase in ENaC current. As in
the mCCD cells, pretreatment with 2:1 ratio of inhibitor to
protease resulted in a reduction in ENaC activation by the AP
protease (Figure 5B, C). The block of ENaC activation was
complete with the super-stoichiometric addition of the Inh protein
(p,0.001). This inhibition was observed with co-treatment of the
AP and Inh proteins or pretreatment with the Inh protein. No
measurable differences were observed between the pretreatment
or co-treatment application of the inhibitor and protease.
ENaC activation by the SmP protein was similarly assessed in
HBE cells. Addition of SmP to the apical chamber resulted in a
sustained increase in ENaC activation, similar to that seen in the
mCCD cells and with AP (Figure 5D, F). This activation was slow
and sustained, resulting in an increase of ,90% ENaC current in
the HBE cells. Treatment with the AP Inh protein blocked this
activation when cells were pretreated with the inhibitor or co-
treated with the protease and inhibitor (p,0.001) (Figure 5E, F).
As with AP and the mCCD cells, no observable changes in ENaC
activity were induced by the inhibitor alone. Similarly, both
pretreatment with the inhibitor or co-treatment of the inhibitor
and protease resulted in a loss of protease-stimulated ENaC
activity.
Figure 5. ENaC regulation in HBE cells by the proteases and the AP inhibitor. The activation of ENaC was assessed in HBE cells by recording
short circuit currents. A, a representative trace showing the activation of ENaC in HBE cells is shown. B, a representative trace of AP treatment after AP
Inh pretreatment is shown. C, quantification of the relative currents seen after treatment with either AP or AP and AP Inh for HBE cells are shown
(n = 9). Basal currents are normalized to 100%. D, a representative trace showing the activation of ENaC by SmP in HBE cells is shown. E, a
representative trace of SmP after AP Inh pretreatment is shown. F, quantification of the relative currents seen after treatment with either SmP or SmP
and AP Inh for HBE cells is shown (n= 5). G, the kinetics of ENaC activation are shown under conditions of maximal stimulation using trypsin, closed
circles, AP, closed tringles, or SmP, open circles. Time constants of ENaC activation are shown for each protease. Serial addition of proteases and
inhibitors is shown by the bars above the current trace and labelled. The period in the recording where the apical chamber was washed to remove
the serine protease inhibitor, camostat, is indicated with a W. Data shown are representative of at least seven experiments. P,0.001, *.
doi:10.1371/journal.pone.0100313.g005
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The kinetics of ENaC activation in HBE cells were similarly
assessed under conditions of maximal stimulation using the AP
and SmP proteins. As with the mCCD cells, the SmP and AP
proteins showed different rates of ENaC activation, which were
both markedly slower than those observed with trypsin (Figure 5G).
Trypsin addition resulted in ENaC activation with a time constant
of 17 s, compared to 177 seconds for SmP (p,0.05) and 350
seconds for AP (p,0.05). The changes in HBE ENaC activation
kinetics qualitatively paralleled those seen in mCCD cells, though
the time constants of activation did differ between the cell lines.
Discussion
Proteolytic activation of ENaC has been postulated to play a key
role in both normal and disease physiologies in the airway [39–
41]. As such, it is possible that both endogenous (host) and
exogenous (pathogen) proteases may play a role in establishing and
remodeling the airway environment. Here we demonstrate that
multiple members of the serralysin metalloprotease family are
capable of activating ENaC. These data suggest that ENaC may
serve as a target for the serralysin virulence factors from multiple
human pathogens. Further, the Pseudomonas aeruginosa AprI,
alkaline protease inhibitor can be effectively used to block the in
vitro activities of purified serralysin proteases and reverse their
effects in physiological experiments on cultured and primary
epithelial cells.
Our previous studies showed that ENaC can be activated by the
addition of AP at the apical surface of cultured and primary
epithelial cells [26]. This activation may contribute to the
virulence of Pseudomonas by remodeling the local airway environ-
ment to be more favorable for bacterial adhesion and subsequent
colonization. The current study demonstrates that this activation is
more general to this class of bacterial exoproteases, as serralysin
from Serratia marcescens is similarly capable of activating ENaC
(Figure 4, 5). This activation is slow when compared to trypsin
under maximal stimulating conditions. The slow activation of
ENaC by both AP and SmP suggest that the physical basis of
activation may also be similar for both proteases. However the
kinetics of ENaC activation were slightly accelerated in SmP
treated epithelia compared to AP (Figure 4G, 5G), in line with the
biophysical characterization of the protease activities (Figure 2).
Binding of the inhibitor to AP and SmP is tight, as measured in
vitro using purified proteins, and completely abolishes protease
activity, consistent with prior reports of binding between the
protease and inhibitor (Figure 3) [19]. This tight in vitro binding is
observed as a complete loss of protease-induced ENaC current in
two different model epithelia (Figures 4 and 5). This inhibition
provides evidence that the activation of ENaC is mediated through
cleavage of a host protein by the bacterial protease. The
coincident inhibition of protease activity and loss of ENaC
activation suggests that the observed activation is occurring
through one or more cleavage events and is not mediated by
other non-catalytic binding or protein-protein interactions.
The AP and SmP mediated activation is slow when compared
to that elicited by trypsin. The kinetics of ENaC activation by AP
and SmP are slowed by ,3.5 to 20 fold when compared to trypsin
in the two cell lines. Though previous studies have demonstrated
that cleavage of the c-subunit is required for AP induced ENaC
activation, it is not immediately clear why the activation kinetics
vary between the trypsin and the bacterial proteases. The
relatively slow and submaximal activation may arise from
conformational constraints limiting access to one or more cleavage
sites in the ENaC ectodomain. This would be consistent with a
model wherein the mechanisms of ENaC cleavage and activation
did not co-evolve with the bacterial proteases. Alternatively, this
slow activation may be the result of indirect activation via an
additional protease-sensitive pathway. Further work to evaluate
these differences in activation kinetics is ongoing.
Both the AP and SmP proteases have been implicated in
bacterial virulence. Previous studies have suggested that AP is
associated with exacerbations in CF and complications in treating
Pseudomonas [2,42–44]. It is not known if these effects are the result
of AP expression, per se, or if they are coincident with the
expression of AP and other Ca2+-regulated virulence factors.
While not generally associated with the lung and CF, Serratia is
often cultured from trachea and is a growing concern as a human
pathogen [45,46]. Adherence and colonization of Serratia in the
trachea would putatively also be modulated by normal muco-
cilliary clearance mechanisms. Alterations in ENaC regulation
may disrupt these normal processes and represent one potential
mechanism by which serralysin facilitates Serratia infection in the
trachea.
Consistent with this, recent work evaluating the effects of Liddle
syndrome mutants in ENaC demonstrates that tracheal tissue is
sensitive to alterations in ENaC activity [47]. Dysregulation of
ENaC results in increased Na+ flux and an increase in fluid
absorption in isolated murine trachea overexpressing b-ENaC
under thin film conditions. Similarly, studies of fluid secretion
using isolated pig and human trachea and specific channel
blockers for CFTR and ENaC demonstrate that both channels
contribute to secretion and ASL fluid maintenance [42,47,48].
Thus, either inhibition or hyper-activation of these channels would
potentially alter fluid balance in the airway [48].
Finally, the inhibition seen with the AP Inh suggests a general
mechanism by which this group of protease virulence factors may
be partially neutralized. The small, soluble protease inhibitor
appears stable and effective for prolonged periods in vitro and
under a variety of physiological conditions. These characteristics
are likely the result of strong selective pressure to protect the
pathogen from unregulated intracellular protease activities. Given
the strong structural similarity between other members of this
family of metalloproteases, it is likely that this inhibitor could
inhibit other structurally similar proteases and may be useful in
efforts to modulate other serrlaysin or related proteases.
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